Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck Partners On Alzheimer’s Diagnostic With GE Healthcare

This article was originally published in The Gray Sheet

Executive Summary

Merck will use GE Healthcare’s investigational positron emission tomography agent flutemetamol to select patients to enroll in clinical trials for its Alzheimer’s disease drug candidate.

You may also be interested in...

Luminex Teams With Merck For Alzheimer’s Companion Diagnostic

The assay will be used to support patient selection as part of Merck’s ongoing clinical trial program for the MK-8931 Alzheimer’s disease drug candidate.

CMS Urged To Cover Beta Amyloid PET Scans For Alzheimer's, But Cautiously

Imaging stakeholders call for Medicare coverage of beta amyloid positron emission tomography scans to help diagnose and manage dementia patients, but clinical societies warn against using the technology as a screening tool for Alzheimer’s disease. CMS took comments through Nov. 8 on its ongoing national coverage analysis.

New Products In Brief

The latest product approvals and launches in cardiology, ophthalmology and more.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts